CEL-SCI (FRA:LSR) Moat Score: 2/10 (As of Jun. 28, 2026)


FRA:LSR CEL-SCI Corp FRA:LSR
30 GF Score
Price €0.76
! 2 Warning Signs
View Full Analysis

What is CEL-SCI Moat Score?

CEL-SCI FRA:LSR -9.52% 30 Moat Score is 2 as of Jun. 28, 2026. GuruFocus rates FRA:LSR with a GF Score™ of 30/100. The stock has 2 warning signs investors should review. Among 1,402 Biotechnology companies, CEL-SCI ranks better than 58.06% on this metric.

CEL-SCI has the Moat Score of 2, which implies that the company might have No Moat - Very weak/transient advantages.

CEL-SCI has No Moat: CEL-SCI operates in the biotech sector with high R&D costs and uncertain product success. The company lacks significant market share, strong brand, or proprietary technology that could provide a sustainable competitive advantage.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes CEL-SCI might have No Moat - Very weak/transient advantages.

CEL-SCI  (FRA:LSR) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

CEL-SCI Moat Score Related Terms

FRA:LSR vs TRAW, QNCX, CRIS: Moat Score Comparison

For the Biotechnology subindustry, CEL-SCI's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

CEL-SCI Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CEL-SCI's Moat Score distribution charts can be found below:

* The bar in red indicates where CEL-SCI's Moat Score falls into.


FRA:LSR
30GF Score
CEL-SCI Corp FRA:LSR
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 2 mean?
CEL-SCI (FRA:LSR) has a Moat Score of 2 as of Jun. 28, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, CEL-SCI ranks #588 out of 1402 companies in the Biotechnology industry, placing it in the top 41.9%.
Is CEL-SCI's Moat Score too high?
CEL-SCI's current Moat Score is 2. The Biotechnology industry median Moat Score is 2.00. CEL-SCI's value of 2 is 0% at this industry median. Based on the distribution chart, CEL-SCI ranks #588 out of 1402 companies in the Biotechnology industry, which is above the industry midpoint. Overall, CEL-SCI has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does CEL-SCI's Moat Score compare to TRAW and QNCX?
According to the Biotechnology industry distribution chart, CEL-SCI ranks #588 out of 1402 companies for Moat Score. This puts CEL-SCI in the upper half of its industry. The industry median Moat Score is 2.00. CEL-SCI's value of 2 is 0% at this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,402 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. CEL-SCI's current Moat Score of 2 is 0% at the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CEL-SCI's current Moat Score is 2. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CEL-SCI stock overvalued right now?
CEL-SCI (FRA:LSR) has a current Moat Score of 2. The current Moat Score is 2 and 0% at the Biotechnology industry median of 2.00. CEL-SCI's overall GF Score™ is 30/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For CEL-SCI (FRA:LSR), the current Moat Score is 2 as of Jun. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

CEL-SCI Business Description

Other Exchanges CVM:USA
Address 8229 Boone Boulevard, Suite 802, Vienna, VA, USA, 22182
CEL-SCI Corp is a late clinical-stage biotechnology company dedicated to research and development directed at improving the treatment of cancer and other diseases by using the immune system, the body's natural defense system. The company is focused on the development of the following product candidates and technologies: 1) Multikine, an investigational Phase 3 immunotherapy under development for the potential treatment of certain head and neck cancers; 2) LEAPS (Ligand Epitope Antigen Presentation System) technology, for the potential treatment of rheumatoid arthritis.
30GF Score

Get the complete analysis for FRA:LSR

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.76
Price